Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974233 | 0.87 | KMT2A (0.41) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2982588 | 0.86 | BTK (0.43) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2977606 | 0.85 | LPAR1 (0.47) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2971243 | 0.85 | KMT2A (0.38) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2986498 | 0.84 | SMN1; SMN2 (0.41) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2975666 | 0.84 | TUBB4A (0.42) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2983462 | 0.84 | GABRA1 (0.39) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2982533 | 0.84 | KMT2A (0.47) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2988129 | 0.83 | MAPT (0.41) | KMT2AMEN1BTKKITKDM4E | |
| SCHEMBL2977934 | 0.81 | MAPT (0.45) | KMT2AMEN1BTKKITKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786113-B2 | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | claimed |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-01-10 | — | — | US | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| US-7786113-B2 | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-01-10 | — | — | US | disclosed |
| EP-1831218-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066914-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | KMT2A 1263/4885MEN1 2351/4885BTK 1856/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | KMT2A 1661/4885MEN1 3328/4885BTK 2456/4885 |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | RCC2, ACMSD, CPS1 | KMT2A 2359/4885MEN1 148/4885BTK 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.